Group 1 - On January 12, BaiOsaite's stock increased by 14.87%, with a trading volume of 425 million yuan [1] - The financing data shows that BaiOsaite had a financing purchase amount of 27.33 million yuan and a financing repayment of 27.84 million yuan, resulting in a net financing buy of -0.51 million yuan [1] - As of January 12, the total balance of BaiOsaite's margin trading was 55.79 million yuan, which accounts for 2.26% of its circulating market value [1] Group 2 - BaiOsaite (Beijing) Pharmaceutical Technology Co., Ltd. was established on November 13, 2009, and is located in the Daxing District of Beijing [2] - The company specializes in antibody drug research and preclinical research services, operating five divisions [2] - The divisions include gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focused on oncology and autoimmune diseases [2]
百奥赛图1月12日获融资买入2733.31万元，融资余额5579.88万元